Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in R/R AML or MDS after HMA failure
NCT02019069Phase 2Completed
- Start
- Feb 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Primary endpoint: Response Rate (RR) at Day 42. Started Feb 2014; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02019069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019069.